This recombinant serine protease inhibitor inhibits both trypsin (Ki=2.5 nM) and chymotrypsin (Ki=30 nM) (PubMed:17447883). It may also inhibit the TRPV1 receptor, a receptor of the pain pathway (By similarity). In vivo, shows anti-histamine activity, since it dose-dependently weakens the clinical manifestation of the allergic reaction induced by histamine injection. In vivo, does not show toxicity to mice by intraperitoneal injection (PubMed:17447883). Belongs to the venom Kunitz-type family. Sea anemone type 2 potassium channel toxin subfamily.